利用双向两样本孟德尔随机化探究DNA甲基化与2型糖尿病关联的因果性
本研究采用双向两样本孟德尔随机化方法,在58个既往与2型糖尿病相关的CpG位点上评估DNA甲基化与2型糖尿病的因果关联。研究发现cg25536676(DHCR24)DNA甲基化转化残差升高与2型糖尿病风险升高43%相关(OR 1.43,95%CI 1.15,1.78,p=0.001),其余位点推断可能因果方向;作者假设DHCR24候选CpG可能是已知可改变危险因素与2型糖尿病关联的因果中介,需正式因果中介分析验证。
要点
- cg25536676(DHCR24)DNA甲基化转化残差升高与2型糖尿病风险升高相关(OR 1.43,95%CI 1.15,1.78,p=0.001)。
- 其余评估的CpG位点推断出可能的因果方向。
- 作者假设DHCR24候选CpG可能是已知可改变危险因素与2型糖尿病关联的因果中介,需正式因果中介分析验证。
核心结论
- 鉴定出cg25536676(DHCR24)为2型糖尿病风险的新型因果生物标志物。
- 作者假设DHCR24候选CpG可能是已知可改变危险因素与2型糖尿病关联的因果中介,需正式因果中介分析进一步验证该假设。
研究设计与样本
- 采用双向两样本孟德尔随机化(2SMR)评估58个CpG位点(既往欧洲人群2型糖尿病表观全基因组关联研究荟萃分析检出)的因果性。
- 从最大规模全基因组关联研究获取2型糖尿病和DNA甲基化的遗传代理;当较大数据集中无相关关联时使用Avon父母与儿童纵向研究(ALSPAC,英国)数据。
- 鉴定62个独立SNP作为2型糖尿病的代理,39个甲基化数量性状位点作为58个2型糖尿病相关CpG中30个的代理。
- 采用Bonferroni校正多重检验,2型糖尿病至DNA甲基化方向以p<0.001推断因果性,DNA甲基化至2型糖尿病方向以p<0.002推断因果性。
主要发现
- cg25536676(DHCR24)DNA甲基化转化残差升高与2型糖尿病风险升高43%相关(OR 1.43,95%CI 1.15,1.78,p=0.001)。
- 对剩余评估的CpG位点推断了可能的因果方向。
- 计算机分析显示所分析CpG富集于表达数量性状甲基化位点(eQTMs)及特定性状,取决于2SMR分析预测的因果方向。
关键数值与推荐
- 2型糖尿病至DNA甲基化方向以p<0.001推断因果性。
- DNA甲基化至2型糖尿病方向以p<0.002推断因果性。
- cg25536676(DHCR24)DNA甲基化转化残差升高与2型糖尿病风险升高43%相关(OR 1.43,95%CI 1.15,1.78,p=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需实施正式因果中介分析以进一步验证DHCR24候选CpG作为因果中介的假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Several studies have identified associations between type 2 diabetes and DNA methylation (DNAm). However, the causal role of these associations remains unclear. This study aimed to provide evidence for a causal relationship between DNAm and type 2 diabetes. METHODS: We used bidirectional two-sample Mendelian randomisation (2SMR) to evaluate causality at 58 CpG sites previously detected in a meta-analysis of epigenome-wide association studies (meta-EWAS) of prevalent type 2 diabetes in European populations. We retrieved genetic proxies for type 2 diabetes and DNAm from the largest genome-wide association study (GWAS) available. We also used data from the Avon Longitudinal Study of Parents and Children (ALSPAC, UK) when associations of interest were not available in the larger datasets. We identified 62 independent SNPs as proxies for type 2 diabetes, and 39 methylation quantitative trait loci as proxies for 30 of the 58 type 2 diabetes-related CpGs. We applied the Bonferroni correction for multiple testing and inferred causality based on p<0.001 for the type 2 diabetes to DNAm direction and p<0.002 for the opposing DNAm to type 2 diabetes direction in the 2SMR analysis. RESULTS: We found strong evidence of a causal effect of DNAm at cg25536676 (DHCR24) on type 2 diabetes. An increase in transformed residuals of DNAm at this site was associated with a 43% (OR 1.43, 95% CI 1.15, 1.78, p=0.001) higher risk of type 2 diabetes. We inferred a likely causal direction for the remaining CpG sites assessed. In silico analyses showed that the CpGs analysed were enriched for expression quantitative trait methylation sites (eQTMs) and for specific traits, dependent on the direction of causality predicted by the 2SMR analysis. CONCLUSIONS/INTERPRETATION: We identified one CpG mapping to a gene related to the metabolism of lipids (DHCR24) as a novel causal biomarker for risk of type 2 diabetes. CpGs within the same gene region have previously been associated with type 2 diabetes-related traits in observational studies (BMI, waist circumference, HDL-cholesterol, insulin) and in Mendelian randomisation analyses (LDL-cholesterol). Thus, we hypothesise that our candidate CpG in DHCR24 may be a causal mediator of the association between known modifiable risk factors and type 2 diabetes. Formal causal mediation analysis should be implemented to further validate this assumption.
引用
- Juvinao-Quintero DL, Sharp GC, Sanderson ECM, et al. Investigating causality in the association between DNA methylation and type 2 diabetes using bidirectional two-sample Mendelian randomisation. Diabetologia. 2023. PMID: 37202507. doi:10.1007/s00125-023-05914-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。